What is Semaglutide?

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It is a synthetic analogue of the endogenous incretin hormone GLP-1, engineered for resistance to enzymatic degradation and for extended circulation time relative to the native peptide. The compound is supplied to research laboratories as a lyophilised powder for reconstitution and is handled as a reference material for in vitro and preclinical work. The evidence block supporting this page does not provide a sequence, molecular formula or molecular weight for semaglutide, so no such values are stated here.

The pharmacological work on this compound centres on the GLP-1 receptor, a class B G-protein-coupled receptor that signals through Gs-coupled cyclic AMP accumulation in pancreatic beta cells and in a range of extra-pancreatic tissues. Semaglutide is described in the analytical literature as a potent long-acting GLP-1 receptor agonist with therapeutic efficacy in type 2 diabetes and obesity [9].

Research Studies

Semaglutide and postpartum cardiometabolic risk after gestational diabetes

A randomised clinical trial is evaluating immediate postpartum semaglutide in individuals whose pregnancy was complicated by gestational diabetes mellitus (GDM). The study is designed as an effectiveness-implementation Hybrid Type 1 trial, randomising 226 postpartum participants 1:1 to semaglutide or standard postpartum care for a 6-month active treatment phase. The primary effectiveness outcome is development of metabolic syndrome, assessed at 6 months postpartum. Participants then enter a 6-month maintenance phase in which continuation, discontinuation or initiation of semaglutide reflects patient and clinician decisions [1].

Semaglutide and cardiometabolic profile in schizophrenia with metabolic syndrome

Patients with schizophrenia receiving second-generation antipsychotics carry a high burden of metabolic syndrome and elevated cardiovascular risk, and the evidence block notes few effective treatment options in this group. A multicentre, double-blind, placebo-controlled randomised trial is testing adjunctive oral semaglutide 3 mg once daily added to treatment as usual. The endpoints are 10-year cardiovascular risk by QRISK3, insulin resistance, lipids, weight and metabolic biomarkers over 24 weeks, alongside psychiatric safety and tolerability [2].

Semaglutide and muscle preservation in older adults with type 2 diabetes

A randomised, double-blind, placebo-controlled trial is examining whether daily calcium beta-hydroxy-beta-methylbutyrate (calcium-HMB) plus vitamin D3 preserves muscle mass, physical function and resting metabolism in adults aged 65 to 85 years with type 2 diabetes who are newly starting semaglutide as part of usual clinical care. Participants receive the supplement combination or matching placebo for approximately 6 months. The primary outcome is change in appendicular lean mass measured by dual-energy X-ray absorptiometry from baseline to month 6, with secondary assessments of body composition, muscle strength, physical performance, gait, physical activity and resting metabolic rate [3].

Semaglutide and switching to zovaglutide in adults with obesity

The HORIZON-SWITCH-SZ study evaluates the safety and tolerability of continuing treatment with zovaglutide injection following titration to 2.4 mg semaglutide injection in adult participants with obesity [4]. This is a switching design rather than a head-to-head efficacy comparison; the stated purpose is safety and tolerability.

Semaglutide dose effects on craving and alcohol use outcomes

A study is comparing two doses of semaglutide, 1.0 mg and 2.0 mg, against placebo in patients with alcohol use disorder and obesity. The outcomes assessed are alcohol craving, stress and alcohol use [5].

Semaglutide and zenagamtide in excess body weight

A research study is investigating how well zenagamtide helps people with excess body weight lose weight compared with semaglutide, with safety and effectiveness as the stated objectives [6].

Semaglutide and early reinitiation after sleeve gastrectomy in youth

A Phase 3a, randomised, parallel-controlled trial compares early reinitiation of semaglutide, starting two weeks after sleeve gastrectomy, with standard care (no pharmacotherapy following surgery). The trial involves 150 youth with severe obesity who had been on semaglutide 2.4 mg weekly for at least 3 months before surgery. Participants are randomised to semaglutide 2.4 mg weekly or standard care for 24 months, with outcomes assessed at 1 month, on the day of surgery, and at 1, 3, 6, 9, 12, 18 and 24 months postoperatively. The investigators hypothesise that early reinitiation will be safe [7].

Semaglutide and structured lifestyle support in breast cancer survivors on aromatase inhibitors

A phase IV trial studies whether adding semaglutide to structured lifestyle support improves heart and blood vessel health in postmenopausal obese breast cancer survivors taking an aromatase inhibitor. In this population, obesity raises the risk of cardiovascular problems. The structured lifestyle support includes counselling on nutrition and physical activity with specific recommendations for individuals to follow [8].

Comparison of trial models

Analytical and observational evidence

Beyond the interventional trials above, the evidence block includes reference material on measurement and on real-world use. A comprehensive review covers analytical methods for determining semaglutide in pharmaceutical formulations and biological matrices, motivated by the demand for techniques to identify the compound in those settings [9]. A community pharmacy-based cross-sectional survey conducted across 28 Danish community pharmacies between March and May 2025 investigated treatment patterns among adult users of semaglutide for weight management, on the premise that users may not follow the recommended treatment regimen [10]. A further analysis addresses neuropsychiatric outcomes with tirzepatide, semaglutide and other GLP-1 receptor agonists, noting that neuropsychiatric safety concerns including depression and suicidal ideation have emerged during expanding clinical use of incretin-based therapies for type 2 diabetes and obesity, while whether risks differ across successive generations of these therapies remains uncertain [11]. A pooled analysis of placebo-controlled STEP trials examines gallbladder-related adverse events with semaglutide 2.4 mg [12].

If you are reading this for personal health reasons

Semaglutide from our catalogue is sold for laboratory research only. We do not provide dosing information or medical guidance of any kind. Anyone considering a compound for their own health should speak to a licensed clinician.

Sources

• [1] Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes — https://clinicaltrials.gov/study/NCT07797036
• [2] Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome — https://clinicaltrials.gov/study/NCT07770282
• [3] HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide — https://clinicaltrials.gov/study/NCT07760948
• [4] A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ) — https://clinicaltrials.gov/study/NCT07812597
• [5] Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes — https://clinicaltrials.gov/study/NCT07772960
• [6] A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide — https://clinicaltrials.gov/study/NCT07668414
• [7] Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth — https://clinicaltrials.gov/study/NCT06934655
• [8] Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors — https://clinicaltrials.gov/study/NCT07769047
• [9] Analytical methods for the determination of semaglutide in pharmaceutical formulations and biological matrices: A comprehensive review — https://pubmed.ncbi.nlm.nih.gov/42664897/
• [10] Treatment Patterns and Experienced Effects of Semaglutide for Weight Management Among Adult Users in Denmark: A Community Pharmacy-Based Cross-Sectional Survey — https://pubmed.ncbi.nlm.nih.gov/42443134/
• [11] Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists — https://pubmed.ncbi.nlm.nih.gov/42420795/
• [12] Gallbladder-Related Adverse Events With Semaglutide 2.4 mg: Pooled Analysis of Placebo-Controlled STEP Trials — https://pubmed.ncbi.nlm.nih.gov/42410302/